Navigation Links
Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 29th Annual Canaccord Adams Global Growth Conference. The details are as follows:

    Date:  Thursday, August 13, 2009
    Time:  10:00 a.m. Eastern
    Location: InterContinental Boston, London Room
    Speaker: Michael Narachi, Chief Executive Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010, and Empatic(TM) which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
3. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
4. Orexigen(R) Therapeutics to Present at Upcoming Meetings
5. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
6. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
7. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
11. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear Therapeutics, ... discovering drugs for metabolic disorders, announced today the ... its Board of Directors (BOD). Mr. Watkins is ... Human Genome Sciences (HGS), and also served as ... Jim Powers , Chairman and CEO of ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... The royalty-free a greement ... develop daclatasvir for 112 low- and m ... --> --> The Medicines Patent Pool (MPP) ... signing an agreement with Bristol-Myers Squibb for daclatasvir, a novel ... of the HCV virus.  The royalty-free licence will enable generic ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):